Our Pipeline

We challenge ourselves to rethink the way medicines are developed,
and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas including ophthalmology, gastroenterology, and hematology.


Biosimilar candidate

  • Molecule Ranibizumab
  • Reference Biologic Lucentis®ii
  • Therapeutic Area Ophthalmology

Biosimilar candidate

  • Molecule Eculizumab
  • Reference Biologic Soliris®iii
  • Therapeutic Area Hematology

Biosimilar candidate

  • Molecule Aflibercept
  • Reference Biologic Eylea®iv
  • Therapeutic Area Ophthalmology

Novel biologic

  • Molecule Ulinastatin-Fc
    Fusion Protein
  • Therapeutic Area Gastroenterology

*Pipeline last updated Oct 2020

  • iPhase I clinical trial was waived for SB11 and SB15
  • iiLucentis® is a registered trademark of Genentech
  • iiiSoliris® is a registered trademark of Alexion
  • ivEylea® is a registered trademark of Regeneron

You are now leaving the Samsung Bioepis website.
Samsung Bioepis provides this link as a courtesy and does not control the content of the site you are about to enter into. Do you wish to continue?

확인 취소
레이어 팝업 닫기